SEC restatements
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. has 2 revised figures in later SEC filings: annual figures whose value in a later filing differs from the value on record first. Each revision below links to both filings.
CIK 0001711754
Most recent revisions
Newest 2 of 2 · as filed · by the latest filing stating each revision
| Figure | On record first | Revised |
|---|---|---|
| Interest expensePeriod ended Dec 31, 2024 | $789.00KFiled Mar 27, 2025 (opens EDGAR in a new tab) | $357.00KFiled May 8, 2025 (opens EDGAR in a new tab) |
| R&D expensePeriod ended Dec 31, 2018 | $1.11MFiled Mar 29, 2019 (opens EDGAR in a new tab) | $3.35MFiled Mar 11, 2020 (opens EDGAR in a new tab) |
A revised figure is not by itself a correction of an error. Companies re-present prior figures for ordinary reasons too, such as a discontinued business, a merger or a new accounting standard. The value on record first is the earliest filing we hold that states the figure; the revised value is the latest revised value on record, linked to the latest filing that states it.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- Every revised figure for this company, with both values and both filings (Analyst)
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/revisions/INMB
MCP tool:
get_revisions ticker=INMB
Not investment advice. Figures are shown as filed with the SEC; each one links to the filing it came from.